June 17, 2009 – Molecular Insight Pharmaceuticals Inc. presented clinical data on a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto.

Trofex, which targets prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells, has the potential to both detect and, when labeled with a therapeutic isotope, to treat metastatic prostate cancer.

In 2008, Molecular Insight initiated clinical studies of Trofex in patients with documented prostate cancer and confirmed hormone refractory metastatic disease. Two internally developed Trofex compounds, MIP-1072 and MIP-1095, were evaluated for their capacity to visualize the disease and to define their pharmacokinetic profiles. Both agents rapidly detected metastatic prostate cancer lesions in soft tissues and bone, confirming that targeting the extracellular domain of PSMA is a viable approach for the molecular targeting of this cancer. The compounds were uniquely able to detect metastases within one to two hours after injection.

As John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development at Molecular Insight Pharmaceuticals, indicated, “Not only does this data demonstrate the capability to rapidly visualize bone metastasis and soft tissue lesions — that may be missed by conventional imaging techniques — imaging can be done in a single day, which is not possible with some of the products currently on the market for imaging recurrent metastatic disease.

Abstract Title:
Targeting Metastatic Prostate Cancer (PCa) in Patients using 123I-MIP 1072 & 123I-MIP 1095
Authors:
J.A. Barrett1; N.D. LaFrance1; R.E. Coleman2; S.J. Goldsmith3; J.B. Stubbs4; N. Petry2; S. Vallabhajosula3; K.P. Maresca1; F. Femia1; M. Stabin4; J.W. Babich1
1Molecular Insight Pharmaceuticals, Inc., Cambridge, MA, 2Duke University, Durham, NC ,3Cornell Medical Center, NY, NY 4, Radiation Dosimetry Systems, Inc, Palo Alto, CA

For more information: www.molecularinsight.com

Related Content

News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
News | Radiation Oncology

September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and ...

Time September 17, 2021
arrow
News | Radiopharmaceuticals and Tracers

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Time September 16, 2021
arrow
News | Radiopharmaceuticals and Tracers

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 10, 2021
arrow
News | PET Imaging

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File ...

Time September 03, 2021
arrow
News | Nuclear Imaging

August 27, 2021 — The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) issued two cooperative ...

Time August 27, 2021
arrow
News | ASTRO

August 11, 2021 — ASTRO announced that it is facilitating measures that seek to ensure optimal health and sanitary ...

Time August 11, 2021
arrow
Subscribe Now